查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034920

全球心房中膈缺損症室間隔缺損封堵器市場：市場規模、佔有率和趨勢分析（2025-2032 年）

Atrial Septal Defect Closure Device & Ventricular Septal Defect Closure Device Market Size, Share & Trends Analysis | Global | 2025-2032
出版日期: | 出版商: iData Research Inc. | 英文 99 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球心房中膈缺損症室間隔缺損封堵器市場報告（至2032年）

2025年全球心房中膈缺損症室間隔缺損封堵器市場規模為1.909億美元。預計該市場將以1.8%的複合年成長率成長，到2032年達到2.157億美元。

本報告涵蓋了全球心房中膈缺損症封堵裝置的市場，包括用於經皮封堵法治療房室間隔缺損的產品。

分析內容包括銷售量、平均售價 (ASP)、治療次數、市場規模、市場佔有率、成長趨勢、到 2032 年的市場預測以及到 2022 年的歷史數據。

市場成長的促進因素包括醫源性心房中膈缺損症病例數的增加、人口結構變化、先天性心臟疾病檢測準確率的提高以及心臟超音波圖普及率的提高。然而，目標患者數量有限和市場飽和預計將限制其進一步成長。

市場概覽

全球心房中膈缺損症室間隔缺損封堵器市場包括用於封閉心臟心室間隔缺損的裝置。這些裝置經經皮植入，穿過缺損處，並在缺損處擴張以形成密封。

許多此類裝置的設計使得心肌組織能夠隨著時間的推移在其上生長。這使得在適當選擇的患者中可以實現長期閉合，避免進行開胸手術修復。

市場需求受到心房中膈缺損症盛行率和檢出率持續上升的驅動。心臟超音波圖和常規心血管篩檢的普及，使得先天性心臟疾病的早期診斷和檢出率更高。

因此，預計心房中隔缺損封堵術的數量將逐步增加。這將帶動心房中隔缺損封堵器市場穩定成長，但由於患者群有限以及已開發地區技術應用較為成熟，整體市場規模仍有限。

市場促進因素

醫源性自閉症譜系障礙

近年來，醫源性心房中膈缺損症的發生率顯著增加。這種成長與經房間隔入路進行的經導管左心房治療數量的增加密切相關。

例如，MitraClip手術、左心耳封堵術、心導管電氣燒灼術和其他左側心臟介入手術都可能導致心房中隔缺損。

根據目前的臨床指南，僅有極少數醫源性心房中隔缺損需要即時封鎖。通常情況下，當患者無法耐受心房水平的分流時，才會考慮封鎖。在指引更強烈地建議對醫源性心房中隔缺損進行封鎖之前，這部分病例在整個心房中隔缺損市場中仍將佔比相對較小。

然而，經導管二尖瓣瓣膜修復和左心耳封堵術是相對常見的介入性手術。即使只有一小部分醫源性心房中隔缺損病例需要即時封堵，這些手術也可能促進成熟的心房中隔缺損封鎖市場逐步成長。

人口統計因素

人口因素也是推動心房中膈缺損症和室間隔缺損封堵器市場成長的因素之一。隨著全球人口的成長，需要進行心房中隔缺損或心室中隔缺損封堵術的患者人數預計將會增加。

雖然 ASD 和 VSD 的治療仍然屬於先天性和結構性心臟疾病的專業領域，但隨著人口基數的擴大，潛在的診斷數量會隨著時間的推移而增加。

此外，開發中國家獲得先進醫療服務的機會增加，正在推動關鍵國際市場的成長。隨著越來越多的患者能夠獲得影像檢查和導管介入治療服務，更多可治療的心臟缺陷有望被發現和治療。

檢測和篩檢的改進

先天性心臟疾病檢測準確率的提高支撐了市場需求。心臟超音波圖和常規心血管篩檢的普及，導致確診的心房中膈缺損症數量增加。

早期診斷有助於醫生判斷缺陷需要後續觀察、經皮閉合或手術修復。此外，篩檢準確性的提高使患者能夠在併發症惡化之前接受治療。

這一趨勢在新興市場尤其重要，因為這些市場醫療服務可近性的提高有望提升先前較低的診斷率。隨著全球診斷體系的不斷完善，預計診斷數量將逐步增加。

市場限制

患者數量有限

心房中膈缺損症和室間隔缺損封堵器市場的主要限制因素是患者數量有限。許多患有心房中膈缺損症（ASD）或心室中隔缺損（VSD）的患者沒有任何症狀，也不需要治療。

這限制了可銷售的設備數量。此外，即使診斷出缺陷，也並非總是需要進行修復手術，後續觀察而無需治療。

此外，許多ASD患者不適合經經皮封堵術。對於原髮型、靜脈竇型或冠狀竇型缺損、嚴重肺動脈高壓、艾森門格症候群、右向左分流、缺損大於38毫米或缺損周圍邊緣組織不足的患者，可能需要開胸手術。

在更多 ASD 和 VSD 得到診斷和經皮治療方法之前，市場將繼續受到合格的患者數量的限制。

市場飽和

用於心房中膈缺損症缺損及室間隔缺損的封堵器市場正日趨飽和。在大多數已開發地區，手術數量保持穩定，目標患者群也十分明確。

由於患者群有限，在成熟市場中大幅提升銷售額的機會不多。預計大部分成長將由診斷技術的進步、新興市場的開拓以及特定新適應症（例如醫源性心房中隔缺損封堵術）所驅動。

隨著市場日趨成熟，製造商之間的競爭日益激烈。由於手術量大幅成長的空間有限，各公司必須在價格、產品知名度、分銷網路和醫生偏好等方面競爭。

價格壓力和差異化程度的局限性

價格壓力也是這個成熟市場中的重要阻礙因素。隨著競爭加劇和手術數量趨於穩定，製造商面臨維持價格合理的壓力。

尤其是在醫生已經熟悉現有封閉式醫療器材平台的市場中，產品差異化可能有限。當產品功能被認為相似時，價格因素會更主導購買決策。

預計這種環境將在預測期內抑制市場價值的整體成長。即使單位需求溫和成長，平均售價（ASP）面臨的壓力也可能限制供應商的收入成長。

市場範圍和數據範圍

  • 定量範圍：市場規模、市場佔有率、手術數量、市場預測、市場成長率、銷售單位數量、平均售價。
  • 定性範圍：市場促進因素和限制因素、競爭分析、近期併購、公司簡介、產品系列和主要競爭對手。
  • 目標時期：基準年為 2025 年，預測至 2032 年，歷史資料截至 2022 年。
  • 建立市場模型：收入分析採用銷售量和平均售價（ASP），並輔以治療量、競爭市場佔有率分析和預測假設。
  • 目標器材：本報告涵蓋用於治療心房中膈缺損症和室間隔缺損的器材。這些器械透過缺損部位插入體內，並擴張以封閉開口周圍的區域。

目標市場及區隔

心房中膈缺損症室間隔缺損封堵器市場

  • 器械類型：房間隔缺損封堵器和室間隔缺損封堵器。

心房中隔缺損封堵器用於封閉心臟兩個心房之間的開口。當缺損適合經經皮封堵且患者無需開胸手術時，最常使用這些封堵器。

室間隔缺損封堵器用於封閉心臟心室之間的開口。這些手術更具選擇性，取決於缺損的類型、位置和大小、患者的解剖結構以及臨床需求。

許多室間隔缺損封堵裝置的設計允許組織隨著時間的推移在裝置上生長，從而維持缺損的長期閉合。

每個細分市場都按市場規模、市場佔有率、治療數量、市場預測、市場成長率、銷售量和平均售價進行分析。

這種細分使製造商、投資者和策略團隊能夠了解診斷率、患者合格、經皮適用性、外科手術替代方案、價格壓力和區域准入狀況如何影響對 ASD 和 VSD 封鎖的需求。

競爭分析

2025年，雅培是全球房間隔缺損和室間隔缺損封堵器市場的領先競爭者。該公司提供「Amplatzer™」系列產品，其中包括用於心房中膈缺損症和室間隔缺損的封堵器。

雅培充分利用自身優勢：搶佔市場先機、獲得醫生認可以及擁有廣泛的全球供應鏈。鑑於在這個市場中真正實現全球企業發展的公司數量有限，預計雅培將在未來幾年內保持其市場佔有率。

Amplatzer™平台仍是室間隔缺損封鎖領域的領先產品線。其良好的口碑鞏固了雅培在該市場的領導地位，在這個市場中，醫生的信任和產品的長期親和性至關重要。

截至2025年，戈爾公司是全球房間隔缺損（ASD）和室間隔缺損（VSD）封堵器市場第二大競爭對手。該公司提供「Gore® Cardioform 房間隔封堵器」。

戈爾公司主要透過區域性管道進入心房封堵市場。雖然其「心形隔膜封堵器」鞏固了該公司在結構性心臟疾病封堵領域的地位，但戈爾公司在某些市場的業務擴張可能會受到小規模的本地公司的限制。

成熟的封閉式醫療器材平台、區域產品供應以及本地供應商之間的競爭仍然是當前市場競爭格局的主要驅動力。隨著市場日趨成熟，擁有強大的分銷網路、久經考驗的醫療器材性能以及完善的醫生培訓支援的企業預計將繼續保持最有利的地位。

科技和醫療治療的發展趨勢

經皮閉合

經皮封堵術仍然是該市場的核心技術和臨床趨勢。該裝置經缺損部位插入後會膨脹形成密封，從而減少符合條件的患者接受開胸手術的必要性。

與手術修復相比，這種方法可以縮短恢復期，並減輕手術負擔。

組織增生和長期密封

許多封堵裝置的設計允許心臟組織隨著時間的推移在裝置上生長，從而在缺陷周圍形成持久的密封。

這項特性有助於提高設備的穩定性，並確保治療的長期成功。

透過心臟超音波圖檢測心房中隔缺損

心臟超音波圖的廣泛應用提高了心房中膈缺損症的檢出率。更早、更準確的診斷可能會導致更多患者接受治療評估。

預計這將導致手術數量逐步增加。

醫源性心房中隔缺損封堵術

隨著經導管左心房手術的增加，醫源性心房中隔缺損（ASD）的重要性也日益凸顯。經心房中隔入路進行的二尖瓣修復、左心耳阻塞和消融手術均可能導致缺損，而這些缺損可能需要進行封鎖。

這目前仍是小規模的應用案例，但未來有擴展的潛力。

手術治療與經皮治療方案

並非所有房間隔缺損和室間隔缺損都適合經經皮封堵。有些患者因缺損的類型、大小、解剖結構或合併症等原因，需要進行開胸手術。

患者選擇仍將是市場需求的核心要素。

成熟市場的市場競爭

在已開發地區，市場已趨於成熟，競爭日益激烈。價格壓力、產品差異化程度有限、區域競爭預計將對供應商績效產生影響。

為了維持市場佔有率，製造商必須依靠臨床認知、設備可靠性和本地市場管道。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

  • 目前全球心房中膈缺損症室間隔缺損封堵器市場規模有多大？預計到 2032 年將成長多少？
  • 銷售量、治療量、平均售價（ASP）和市場規模如何隨時間變化？
  • ASD 和 VSD 封堵裝置在治療先天性和結構性心臟疾病中扮演什麼角色？
  • 心臟超音波圖普及程度的提高對診斷率有何影響？
  • 經導管治療左心房導致的醫源性心房中隔缺損如何產生新的需求？
  • 為什麼目標患者數量有限會限制整體市場潛力？
  • 經皮縫合術還是開胸手術，哪種手術方式比較適合哪位病人？
  • 市場飽和度如何影響定價與競爭？
  • 全球ASD和VSD封堵器市場的主要企業有哪些？
  • 在競爭格局中，雅培和戈爾處於什麼地位？

iData Research 的《全球心房中膈缺損症(ASD) 和室間隔缺損 (VSD) 封堵器市場報告》透過設備層面的分析、基於手術的建模、平均售價 (ASP) 數據、企業市場占有率分析以及到 2032 年的預測，解答了這些問題。該報告可用於評估需求、對標競爭對手、了解隔膜封堵趨勢以及製定全球 ASD 和 VSD 封堵器市場的產業計畫。

目錄

調查方法

  • 第一步：專案啟動與團隊組建
  • 步驟 2：準備資料系統並進行二次調查。
  • 步驟 3：設計和準備訪談和調查問卷。
  • 第四步：進行初步調查
  • 第五步：調查與分析：建立基準估計值
  • 第六步：市場預測與分析
  • 步驟 7：辨識策略機遇
  • 步驟 8：最終審核和市場推廣
  • 步驟九：客戶回饋與市場監測

全球關稅的影響

心房中隔缺損封堵器市場

  • 執行摘要
    • 全球心房隔缺損封堵器市場概覽
    • 競爭分析
    • 目標程式
    • 目標市場
    • 目標區域
  • 介紹
  • 手術次數
    • 房室間隔缺損完全修補術
    • 心房中隔缺損封堵術
    • 室間隔缺損封堵術
  • 市場概覽
    • 按細分市場
    • 按地區
  • 市場分析與預測
    • 心房中隔缺損封堵器整體市場
    • 心房中隔缺損封堵器市場
    • 室間隔缺損封堵器市場
  • 促進因素和抑制因素
  • 競爭性市佔率分析

附錄

Product Code: iDATA_GLCS26_ASD_MC

Global Atrial and Ventricular Septal Defect Closure Device Market Report to 2032

The global atrial and ventricular septal defect closure device market was valued at $190.9 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.8%, reaching $215.7 million by 2032.

This report covers the global market for atrial and ventricular septal defect closure devices, including products used to treat atrial septal defects and ventricular septal defects through percutaneous closure.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by iatrogenic ASD cases, demographic factors, improved detection of congenital heart defects, and expanded access to echocardiography. However, limited patient population size and market saturation are expected to constrain stronger growth.

Market Overview

The global atrial and ventricular septal defect closure device market includes devices used to close openings in the septum between the heart's chambers. These devices are placed percutaneously through the defect, where they expand and form a seal.

Many of these devices are designed to allow heart tissue to grow over the device over time. This supports long-term closure while avoiding the need for open surgical repair in appropriately selected patients.

Market demand is supported by sustained prevalence and improved detection of atrial septal defects. Expanded access to echocardiography and routine cardiovascular screening has led to earlier diagnosis and increased identification of congenital heart defects.

As a result, procedural volumes for ASD closure are expected to increase modestly. This contributes to stable growth in the septal defect closure device market, although the overall market remains limited by a narrow treatable patient pool and mature adoption in developed regions.

Market Drivers

Iatrogenic ASD

The prevalence of iatrogenic atrial septal defects has increased dramatically in recent years. This growth is linked to the rising number of left atrial transcatheter procedures performed through a transeptal approach.

Examples include MitraClip procedures, left atrial appendage closure, cardiac ablation, and other left-sided interventions. These procedures can create atrial septal defects as part of the access pathway.

Based on current clinical guidelines, only a small percentage of iatrogenic ASDs require immediate closure. Closure is usually considered when the patient cannot tolerate shunting at the atrial level. Until guidelines more strongly reinforce closure of iatrogenic ASD, this will remain a relatively small segment of the total ASD market.

However, transcatheter mitral valve repair and LAA closure are relatively high-volume procedures. Even a small percentage of iatrogenic ASD cases requiring immediate closure could drive modest growth in the mature ASD market.

Demographic Factors

Demographic factors also support growth in the atrial and ventricular septal defect closure device market. As the global population increases, the number of patients requiring ASD or VSD closure is expected to rise.

Although ASD and VSD treatment remains a specialized congenital and structural heart market, a larger population base increases the number of potential diagnoses over time.

In addition, improved access to advanced healthcare in developing economies is driving growth in key international markets. As more patients gain access to diagnostic imaging and interventional cardiology services, more treatable defects may be identified and addressed.

Improved Detection and Screening

Improved detection of congenital heart defects is supporting market demand. Expanded access to echocardiography and routine cardiovascular screening has increased the identification of atrial septal defects.

Earlier diagnosis can help physicians determine whether a defect requires monitoring, percutaneous closure, or surgical repair. Better screening also allows patients to enter the treatment pathway before complications become more severe.

This trend is especially important in emerging markets, where improved healthcare access can raise diagnosis rates from historically lower levels. As diagnostic pathways strengthen globally, procedural volumes are expected to increase modestly.

Market Limiters

Limited Patient Population

The main limiter of the atrial and ventricular septal defect closure device market is the limited patient population. Many people with ASDs or VSDs never show symptoms and do not require treatment.

This limits the number of devices that can be sold. Even when a defect is diagnosed, closure is not always necessary, and patients may be monitored rather than treated.

Many ASD patients are also not suitable for percutaneous closure. Patients with primum, sinus venosus, or coronary sinus type defects, severe pulmonary hypertension, Eisenmenger syndrome, net right-to-left shunt, defects larger than 38 mm, or insufficient rim tissue around the defect may require open surgery instead.

Until more ASDs and VSDs are diagnosed and treated through percutaneous methods, the market will remain constrained by patient eligibility.

Market Saturation

The atrial and ventricular septal defect closure device market has become increasingly saturated. In most developed regions, procedural volumes have stabilized, and the addressable patient population is well defined.

Because the patient pool is limited, there are few opportunities for significant unit growth in mature markets. Most growth is expected to come from improved diagnosis, emerging market access, and selected new indications such as iatrogenic ASD closure.

Market maturity has also intensified competition among manufacturers. With limited room for major procedural expansion, companies must compete on pricing, product familiarity, distribution, and physician preference.

Pricing Pressure and Limited Differentiation

Pricing pressure is another important limiter in this mature market. As competition increases and procedural volumes stabilize, manufacturers face pressure to maintain affordability.

Device differentiation can also be limited, especially in markets where physicians are already familiar with established occluder platforms. When products are viewed as similar in function, purchasing decisions may become more price-sensitive.

This environment is expected to restrain overall market value growth over the forecast period. Even if unit demand rises modestly, ASP pressure may limit the revenue benefit for suppliers.

Market Coverage and Data Scope

  • Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
  • Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
  • Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
  • Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
  • Device scope: The report covers devices used to treat atrial and ventricular septal defects percutaneously by inserting a device through the defect, where it expands and forms a seal around the opening.

Markets Covered and Segmentation

Atrial and Ventricular Septal Defect Closure Device Market

  • Device type: Atrial septal defect closure devices and ventricular septal defect closure devices.

Atrial septal defect closure devices are used to close openings between the atrial chambers of the heart. These devices are most often used when the defect is suitable for percutaneous closure and the patient does not require open surgery.

Ventricular septal defect closure devices are used to close openings between the ventricular chambers of the heart. These procedures are more selective and depend on defect type, location, size, patient anatomy, and clinical need.

Many septal defect closure devices are designed so that tissue can grow over the device with time, supporting long-term sealing of the defect.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how ASD and VSD closure demand is shaped by diagnosis rates, patient eligibility, percutaneous suitability, surgical alternatives, pricing pressure, and regional access.

Competitive Analysis

Abbott was the leading competitor in the global ASD and VSD closure device market in 2025. The company offers the Amplatzer(TM) line, which includes both atrial septal defect and ventricular septal defect closure devices.

Abbott benefits from its early market presence, physician familiarity, and broad global availability. Because there are a limited number of companies with a true global presence in this market, Abbott is expected to maintain its share over the coming years.

The Amplatzer(TM) platform remains a key product line in septal defect closure. Its established use supports Abbott's leadership in a market where physician confidence and long-term product familiarity are important.

Gore was the second-leading competitor in the global ASD and VSD closure device market in 2025. The company offers the Gore(R) Cardioform Septal Occluder.

Gore participates mainly in the atrial closure market regionally. Although the Cardioform Septal Occluder supports the company's position in structural heart closure, smaller local companies may limit Gore's expansion in some markets.

The competitive landscape remains shaped by established occluder platforms, regional product availability, and local supplier competition. As the market matures, companies with strong distribution, proven device performance, and physician training support are expected to remain best positioned.

Technology and Practice Trends

Percutaneous Closure

Percutaneous closure remains the central technology and practice trend in this market. Devices are inserted through the defect and expand to create a seal, reducing the need for open surgery in suitable patients.

This approach supports shorter recovery and lower procedural burden compared with surgical repair.

Tissue Overgrowth and Long-Term Sealing

Many closure devices are designed to allow heart tissue to grow over the device over time. This helps create a long-term seal around the defect.

This feature supports device stability and long-term procedural success.

ASD Detection Through Echocardiography

Expanded access to echocardiography is improving detection of atrial septal defects. Earlier and more accurate diagnosis can increase the number of patients evaluated for treatment.

This is expected to support modest procedural volume growth.

Iatrogenic ASD Closure

Iatrogenic ASD is becoming more relevant as left atrial transcatheter procedures increase. Mitral repair, LAA closure, and ablation procedures performed through transeptal access can create defects that may occasionally require closure.

This remains a small but potentially growing use case.

Surgical Versus Percutaneous Selection

Not all ASDs or VSDs are suitable for percutaneous closure. Some patients require open surgery because of defect type, size, anatomy, or associated conditions.

Patient selection will remain central to market demand.

Mature Market Competition

In developed regions, the market is mature and highly competitive. Pricing pressure, limited differentiation, and local competition are expected to shape supplier performance.

Manufacturers will need to rely on clinical familiarity, device reliability, and regional access to maintain share.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

  • How large is the global atrial and ventricular septal defect closure device market today, and how much is it expected to grow through 2032?
  • How are unit sales, procedure numbers, ASPs, and market values changing over time?
  • What role do ASD and VSD closure devices play in congenital and structural heart treatment?
  • How is improved echocardiography access affecting diagnosis rates?
  • How are iatrogenic ASDs creating new demand after left atrial transcatheter procedures?
  • Why does the limited patient population constrain total market potential?
  • Which patients are suitable for percutaneous closure versus open surgery?
  • How is market saturation affecting pricing and competition?
  • Which companies lead the global ASD and VSD closure device market?
  • How are Abbott and Gore positioned in the competitive landscape?

The Global Atrial and Ventricular Septal Defect Closure Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand septal closure trends, and support commercial planning in the global ASD and VSD closure device market.

TABLE OF CONTENT

Research Methodology

  • Step 1: Project Initiation & Team Selection
  • Step 2: Prepare Data Systems And Perform Secondary Research
  • Step 3: Preparation For Interviews & Questionnaire Design
  • Step 4: Performing Primary Research
  • Step 5: Research Analysis: Establishing Baseline Estimates
  • Step 6: Market Forecast And Analysis
  • Step 7: Identify Strategic Opportunities
  • Step 8: Final Review And Market Release
  • Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Atrial & Ventricular Septal Defect Closure Device Market

  • 23.1 Executive Summary
    • 23.1.1 Global Atrial & Ventricular Septal Defect Closure Device Market Overview
    • 23.1.2 Competitive Analysis
    • 23.1.3 Procedures Included
    • 23.1.4 Markets Included
    • 23.1.5 Regions Included
  • 23.2 Introduction
  • 23.3 Procedure Numbers
    • 23.3.1 Total Atrial And Ventricular Septal Defect Closure Procedures
    • 23.3.2 Atrial Septal Defect Closure Procedures
    • 23.3.3 Ventricular Septal Defect Closure Procedures
  • 23.4 Market Overview
    • 23.4.1 By Segment
    • 23.4.2 By Region
  • 23.5 Market Analysis And Forecast
    • 23.5.1 Total Atrial & Ventricular Septal Defect Closure Device Market
    • 23.5.2 Atrial Septal Defect Closure Device Market
    • 23.5.3 Ventricular Septal Defect Closure Device Market
  • 23.6 Drivers And Limiters
    • 23.6.1 Market Drivers
    • 23.6.2 Market Limiters
  • 23.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

  • Chart 23-1: Atrial & Ventricular Septal Defect Closure Device Market, Global, 2025 & 2032
  • Chart 23-2: Atrial & Ventricular Septal Defect Closure Device Procedures, Global, 2025
  • Chart 23-3: Atrial And Ventricular Septal Defect Closure Procedures by Segment, Global, 2022 - 2032
  • Chart 23-4: Atrial & Ventricular Septal Defect Closure Device Market by Segment, Global, 2022 - 2032
  • Chart 23-5: Atrial & Ventricular Septal Defect Closure Device Market by Region, Global, 2022 - 2032
  • Chart 23-6: Leading Competitors, Atrial & Ventricular Septal Defect Closure Device Market, Global, 2025

LIST OF FIGURES

  • Figure 23-1: Atrial & Ventricular Septal Defect Closure Procedures Covered
  • Figure 23-2: Atrial & Ventricular Septal Defect Closure Device Markets Covered
  • Figure 23-3: Atrial & Ventricular Septal Defect Closure Device Market Regions Covered, Global (1 of 2)
  • Figure 23-4: Atrial & Ventricular Septal Defect Closure Device Market Regions Covered, Global (2 of 2)
  • Figure 23-5: Atrial And Ventricular Septal Defect Closure Procedures by Type, Global, 2022 - 2032
  • Figure 23-6: Atrial And Ventricular Septal Defect Closure Procedures by Region, Global, 2022 - 2032
  • Figure 23-7: Atrial And Ventricular Septal Defect Closure Procedures by Country, North America, 2022 - 2032
  • Figure 23-8: Atrial And Ventricular Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 23-9: Atrial And Ventricular Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 23-10: Atrial And Ventricular Septal Defect Closure Procedures by Country, Western Europe, 2022 - 2032
  • Figure 23-11: Atrial And Ventricular Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 23-12: Atrial And Ventricular Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 23-13: Atrial And Ventricular Septal Defect Closure Procedures by Country, Middle East, 2022 - 2032
  • Figure 23-14: Atrial And Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 23-15: Atrial And Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 23-16: Atrial And Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 23-17: Atrial And Ventricular Septal Defect Closure Procedures by Country, Africa, 2022 - 2032
  • Figure 23-18: Atrial Septal Defect Closure Procedures by Region, Global, 2022 - 2032
  • Figure 23-19: Atrial Septal Defect Closure Procedures by Country, North America, 2022 - 2032
  • Figure 23-20: Atrial Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 23-21: Atrial Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 23-22: Atrial Septal Defect Closure Procedures by Country, Western Europe, 2022 - 2032
  • Figure 23-23: Atrial Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 23-24: Atrial Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 23-25: Atrial Septal Defect Closure Procedures by Country, Middle East, 2022 - 2032
  • Figure 23-26: Atrial Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 23-27: Atrial Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 23-28: Atrial Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 23-29: Atrial Septal Defect Closure Procedures by Country, Africa, 2022 - 2032
  • Figure 23-30: Ventricular Septal Defect Closure Procedures by Region, Global, 2022 - 2032
  • Figure 23-31: Ventricular Septal Defect Closure Procedures by Country, North America, 2022 - 2032
  • Figure 23-32: Ventricular Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 23-33: Ventricular Septal Defect Closure Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 23-34: Ventricular Septal Defect Closure Procedures by Country, Western Europe, 2022 - 2032
  • Figure 23-35: Ventricular Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 23-36: Ventricular Septal Defect Closure Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 23-37: Ventricular Septal Defect Closure Procedures by Country, Middle East, 2022 - 2032
  • Figure 23-38: Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 23-39: Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 23-40: Ventricular Septal Defect Closure Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 23-41: Ventricular Septal Defect Closure Procedures by Country, Africa, 2022 - 2032
  • Figure 23-42: Atrial & Ventricular Septal Defect Closure Device Market by Segment, Global, 2022 - 2032 (US$M)
  • Figure 23-43: Atrial & Ventricular Septal Defect Closure Device Market by Region, Global, 2022 - 2032 (US$M)
  • Figure 23-44: Atrial & Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-45: Units Sold by Region, Atrial & Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-46: Average Selling Price by Region, Atrial & Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032 (US$)
  • Figure 23-47: Market Value by Region Atrial & Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032 (US$M)
  • Figure 23-48: Atrial Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-49: Units Sold by Region, Atrial Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-50: Average Selling Price by Region, Atrial Septal Defect Closure Device Market, Global, 2022 - 2032 (US$)
  • Figure 23-51: Market Value by Region, Atrial Septal Defect Closure Device Market, Global, 2022 - 2032 (US$M)
  • Figure 23-52: Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-53: Units Sold by Region, Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032
  • Figure 23-54: Average Selling Price by Region, Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032 (US$)
  • Figure 23-55: Market Value by Region, Ventricular Septal Defect Closure Device Market, Global, 2022 - 2032 (US$M)
  • Figure 23-56: Leading Competitors, Atrial & Ventricular Septal Defect Closure Device Market, Global, 2025